RMD
ResMed Inc
NYSE: RMD · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$198.76
+0.89% today
Updated 2026-06-05
Market cap
$28.25B
P/E ratio
18.80
P/S ratio
5.10x
EPS (TTM)
$10.36
Dividend yield
1.21%
52W range
$180 – $292
Volume
1.4M
WallStSmart proprietary scores
73
out of 100
Grade: B
Buy
Investment rating
6.7
Growth
B9.5
Quality
A+9.0
Profitability
A+4.7
Valuation
C6/9
Piotroski F-Score
Moderate
4.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$293.70
+47.77%
12-Month target
$228.51
+14.97%
Intrinsic (DCF)
$204.63
Margin of safety
-26.87%
2 Strong Buy9 Buy7 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.34 — safe zone
+ Profit margin 27.40% — above average
+ ROE 23.41% — strong efficiency
+ Free cash flow $520.48M — positive
+ Revenue growth 10.80% QoQ
Risks
- 26.87% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $3.58B | $4.22B | $4.69B | $5.15B | $5.54B | $5.7B |
| Net income | $779.44M | $897.56M | $1.02B | $1.40B | $398.73M | — |
| EPS | — | — | — | — | $10.36 | $11.12 |
| Free cash flow | $195.11M | $559.30M | $1.29B | $1.66B | $520.48M | — |
| Profit margin | 21.78% | 21.25% | 21.79% | 27.22% | 27.40% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-08 | FARRELL, MICHAEL J. | Sale | 4,991 | $193.96 |
| 2026-06-08 | FARRELL, MICHAEL J. | Sale | 4,991 | — |
| 2026-06-01 | RIDER, MICHAEL J | Sale | 269 | $190.57 |
Peer comparison
Smart narrative
ResMed Inc trades at $198.76. representing a P/E of 18.80x trailing earnings. Our Smart Value Score of 73/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 4.34, it sits in the safe zone. TTM revenue stands at $5.54B. with profit margins at 27.40%. Our DCF model estimates intrinsic value at $204.63.
Frequently asked questions
What is ResMed Inc's stock price?
ResMed Inc (RMD) trades at $198.76, on a P/E of 18.8x and a P/S of 5.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is ResMed Inc overvalued?
ResMed Inc carries a Smart Value Score of 73/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $204.63 against the $198.76 price, so on cash flow terms the market is paying a premium for ResMed Inc's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of ResMed Inc (RMD)?
The 12-month analyst consensus target is $293.70, about 47.8% above the current $198.76. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of RMD by 2030?
Our research-backed model puts the 2030 base case at $627.45, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of ResMed Inc (RMD)?
Our DCF model estimates intrinsic value at $204.63, a -26.9% margin of safety versus today's $198.76. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is ResMed Inc's revenue?
ResMed Inc's trailing twelve-month revenue is $5.54B, and our model projects it reaching about $7.50B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
ResMed Inc's Altman Z-Score is 4.34, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio5.10x
ROE23.41%
Beta0.78
50D MA$209.95
200D MA$244.27
Shares out0.15B
Float0.14B
Short ratio—
Avg volume1.4M
Performance
1 week+0.00%
1 month-6.19%
3 months-13.00%
YTD-18.61%
1 year—
3 years—
5 years—